Thank you for your comment. We are evaluating the best path forward based on safety dossier requirements for topical applications. Longer term, we envision that the product should be a prescription based.

Re your comment about founders' experience, we are four founders (three full time Professors, and a senior scientist), with academic and translational portfolio.